



# Prevention and Management of Diabetes Related Foot Problems

## The Law According to NICE

**Dr Ketan Dhatariya** MSc MD MS FRCP

Consultant in Diabetes and Endocrinology  
Norfolk and Norwich University Hospitals



**NICE** National Institute for  
Health and Care Excellence



# Diabetic foot problems: prevention and management


NICE guideline

Published: 26 August 2015

[nice.org.uk/guidance/ng19](https://www.nice.org.uk/guidance/ng19)

# Writing the Guideline

- Guidelines Group
  - Clinical experts
  - Patient representatives
  - National Institute for Health and Care Excellence (NICE) members
  
- Reviewing evidence




# Care Across all Settings

- Training and competency
- Special arrangements for people with disabilities
- Integrated pathways
  - Screening
  - Foot Protection Service
  - Multidisciplinary Foot Service
  - Orthoses and footwear

# Key Priorities for Implementation

- Care within 24 hours of a person being admitted to hospital
- Care across all care settings
- Assessing the risk of developing a diabetic foot problem
- Diabetic foot problems
- Diabetic foot infection
- Charcot arthropathy

# Assessing the risk





# Diabetic Foot Problems

- Low risk (0 risk factors)
  - Annual foot assessment and education
- Moderate (1 risk factor)
  - Referred to Foot Protection Service, for new patient assessment in 6-8 weeks
  - Follow up 3-6 months
- High (2+ risk factors)
  - Refer to Foot Protection Service, for new patient assessment within 2-4 weeks
  - Follow up 1-2 months no immediate concern
  - 1-2 weeks immediate concern (picture)



# Active Diabetic Foot Problems

- Refer people with active diabetic foot problems with 1 working day to the Foot Protection Service or Multidisciplinary Foot Service according to local protocols and pathways
- Triaged within 1 further working day
- Remember the undiagnosed increased risk of cardiovascular disease



# Limb and Life Threatening

Immediate referral to acute services for limb or life threatening diabetic foot problems



# Hospital Acquired Ulceration

All moderate and high risk patients are given pressure redistribution devices



	2010	2011	2012	2013
Patients who developed a foot lesion during their admission	2.2% (257)	N/A	1.6% (210)	1.4% (196)

# Texas Classification

		Grade/Depth "How deep is the wound?"							
		0		1		2		3	
Stage/Comorbidities "Is the wound infected, ischemic or both?"	<b>A</b>	Pre- or post ulcerative lesion completely epithelialised		Superficial wound not involving tendon, capsule or bone		Wound penetrating to tendon or capsule		Wound penetrating to bone or joint	
	<b>B</b>	With infection		With infection		With infection		With infection	
	<b>C</b>	With ischemia		With ischemia		With ischemia		With ischemia	
	<b>D</b>	With infection and ischemia		With infection and ischemia		With infection and ischemia		With infection and ischemia	


# SINBAD Classification

## SINBAD SCORING for Index Ulcer:

Please tick (✓) yes or no on each line

Site= Index Ulcer Hindfoot	No		Yes	
Ischaemia: Clinical PAD?	No		Yes	
Neuropathy: Sensory loss?	No		Yes	
Bacterial infection: Clinical?	No		Yes	
Area: 1cm <sup>2</sup> or more?	No		Yes	
Depth: to tendon or bone?	No		Yes	

# Diabetic Foot Ulcer Management



# Diabetic Foot Infection

- Use soft tissue or bone samples from the base of a debrided wound
- Locally developed antibiotic guidelines
- Consider osteomyelitis
- X-ray
- Consider MRI if x-ray inconclusive



# The Foot Formulary

Quick Reference Guideline Table 2: Antibiotic Management of Diabetes Related Foot Infections In Adults

	FIRST CHOICE		PENICILLIN ALLERGY		DURATION
	PARTIAL OR FULL THICKNESS	EXTENDING TO UNDERLYING SOFT TISSUE/ BONE	PARTIAL OR FULL THICKNESS	EXTENDING TO UNDERLYING SOFT TISSUE/ BONE	
<b>MILD#</b>	Co-amoxiclav 625mg tds PO	Co-amoxiclav 625mg tds PO	Clarithromycin 500mgs bd PO	Clarithromycin 500mgs bd PO Metronidazole 400mgs tds PO	Review after 1-2 weeks. May require an additional 1-2 weeks of treatment. See guidance below re LFT monitoring if treatment continues beyond 2 weeks
<b>MODERATE#</b>	Co-amoxiclav 625mgs tds PO  If co-amoxiclav has previously been used with no success then consider using Clindamycin 150mg-300mg qds PO instead	Co-amoxiclav 625mgs tds PO +/- Ciprofloxacin 500mgs bd PO  If co-amoxiclav has previously been used with no success then consider using Clindamycin 150mg-300mg qds PO instead of co-amoxiclav See guidance note 2 & 5 re adding in ciprofloxacin	Clindamycin 150mg - 300mg qds PO	Clindamycin 150mg-300mg qds PO +/- Ciprofloxacin 500mgs bd PO  (see guidance note 2 & 5 below re adding in ciprofloxacin)	2-4 weeks
<b>SEVERE BORDERLINE ADMISSION</b>  (this regimen will be reviewed regularly as to whether admission is necessary)	Ceftriaxone 1-2g od IM* (see notes below re IM administration) Ciprofloxacin 500mgs bd PO Metronidazole 400mg tds PO  If MRSA positive use teicoplanin in place of ceftriaxone.		Ceftriaxone 1-2g od IM* (see notes below re IM administration) Ciprofloxacin 500mgs bd PO Metronidazole 400mg tds PO  See guidance note 1 below re penicillin allergy. In true penicillin allergy or if MRSA positive use  Teicoplanin IM* 400mg od (see notes below re IM administration) Ciprofloxacin 500mg bd PO Metronidazole 400mg tds PO		2-4 weeks
<b>SEVERE NEEDS ADMISSION</b>	Tazocin 4.5g tds IV  If polymicrobial infection suspected with MRSA then add in vancomycin 1g bd IV to the above. (see guidance notes 3 below)		Clarithromycin 500mg bd IV Metronidazole 400mg tds IV Ceftazidime 1g tds IV (2g tds IV if very severe). Substitute with Ciprofloxacin 500mg bd PO in true penicillin allergy. (see guidance note 1)  If polymicrobial infection suspected with MRSA then add in vancomycin 1g bd IV to the above regimen (omitting clarithromycin). See guidance note 3.		2-4 weeks

\*IM antibiotics should only be given where there are appropriate facilities available to treat anaphylaxis. Ceftriaxone 2g IM should be given as two separate 1g injections in different sites.

# If patient is MRSA positive then prescribe according to sensitivities (combination of 2 of the following oral antibiotics, doxycycline, trimethoprim, rifampicin, fusidic acid (but do not use fusidic acid in combination with rifampicin). Discuss with a Medical Microbiologist on 4588 if sensitivities not available.

Co-amoxiclav may cause cholestatic jaundice if use is prolonged, especially in patients over 65 years. If treatment continues over 2 weeks liver function tests (LFTs) should be carried out. Cholestatic jaundice may occur up to 6 weeks after treatment is stopped.

# Charcot Arthropathy

- Simple fractures can progress to CA
- Suspect CA redness, warmth, swelling and/or deformity with or without pain
- Advise or arrange for non-weight bearing until assessment by MD/FS
- Treat with a non-removable off-loading device
- Monitor temperature, serial x-rays



# Challenges of Implementation

- Resources
  - Capacity of Foot Protection Service & Multidisciplinary Foot Service
  - Waiting times
- Integration
  - Effective and timely communication
  - Agreeing local pathways and policies
  - Centralisation of vascular services
- Training & Competency
  - Staff turnover, recruitment
  - Backfill for training



# Prevention and Management of Diabetes Related Foot Problems The Law According to NICE

[www.norfolkdiabetes.com](http://www.norfolkdiabetes.com)

[ketan.dhatariya@nnuh.nhs.uk](mailto:ketan.dhatariya@nnuh.nhs.uk)

 [@ketandhatariya](https://twitter.com/ketandhatariya)

